Cardiovascular Systems

Traded on the St. Petersburg Stock Exchange
Cardiovascular Systems, Inc. is providing solutions for the revascularization of patients with complex coronary and peripheral artery disease (PAD).
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Cardiovascular Systems balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Cardiovascular Systems cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Cardiovascular Systems multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Cardiovascular Systems profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Cardiovascular Systems assets
Cardiovascular Systems cash flows
Cardiovascular Systems news
28.04.2023
Abbott has completed acquisition of Cardiovascular Systems for $890 million.
Source: {source} pictogram abbott.com
Pictogram next
09.02.2023
Abbott is buying Cardiovascular Systems for $890 million, or $20 per share. Transaction is subject to CSI shareholder approval and customary closing conditions, including applicable regulatory approvals.
Source: {source} pictogram investors.csi360.com
Pictogram next
04.05.2022
Cardiovascular Systems' GAAP loss for 9 months of fiscal year 2022 was $27.243 million, up 3.3 times from $8.136 million in the prior year. Revenue decreased 7.6% to $173.726 million from $187.986 million a year earlier.
Source: {source} pictogram investors.csi360.com
Pictogram next
03.02.2022
Cardiovascular Systems' GAAP loss for 6 months of fiscal year 2022 was $17.585 million, up 8.2 times from $2.132 million in the prior year. Revenue decreased 5.8% to $117.505 million from $124.713 million a year earlier.
Source: {source} pictogram investors.csi360.com
Pictogram next
All Cardiovascular Systems news
General information
Company nameCardiovascular Systems
Tags#medtech
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment
Business address1225 OLD HWY 8 NW ST. PAUL MN 55112 651-259-1600
Mailing address1225 OLD HWY 8 NW ST. PAUL MN 55112
Websitewww.csi360.com
Information disclosurewww.sec.gov